Part : Patient with any advanced or metastatic solid tumor
Part A: Patient with any advanced or metastatic solid tumor
Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK//, ROS, or ALK gene rearrangement
For Phase b, must have advanced refractory solid tumors in any line of therapy.
Histologically or cytologically confirmed diagnosis of selected locally advanced or metastatic solid tumors
Phase  ONLY: histologically or cytologically confirmed advanced/metastatic solid tumors for which carboplatin/etoposide treatment is considered appropriate.
Dose escalation: Histologically or cytologically confirmed diagnosis of unresectable/locally advanced and/or metastatic HER+ solid tumor malignancy and for which standard therapies are not available, are no longer effective, are not tolerated, or have been declined by the patient. Expansion cohort: Locally advanced or metastatic HER+ solid tumors considered likely to respond to a HER-targeted CD agonist (e.g. gastric/gastroesophageal/esophageal, breast, bladder).
Histologically proven, locally advanced unresectable or metastatic solid tumors or hematologic malignancies for whom no approved therapy with demonstrated clinical benefit is available or standard treatment was declined.
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor (including non-Hodgkin Lymphoma) (Stage IV, AJCC v.) that harbors an ALK, ROS, NTRK, NTRK, or NTRK gene rearrangement by protocol specified tests.
Histologically or cytologically documented, injectable cancer lesion (limited to solid tumors and mycosis fungoides)
Pathologically-confirmed, locally advanced or metastatic solid tumors that have relapsed or are refractory to or are not considered medically suitable to receive standard of care treatment (Dose Escalation Phase)
have metastatic or unresectable advanced solid tumors that have recurred or progressed following standard therapy or
Histologically or cytologically confirmed advanced solid tumors including:
Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and have received, or been intolerant to, or been ineligible for all treatment known to confer clinical benefit. Participants with solid tumors of any type are eligible for enrollment.
During Phase , subjects with locally advanced or metastatic solid tumors with disease progression on or after treatment with available therapies, or who are intolerant to treatment, or who refuse standard treatment.
Histologic documentation of locally advanced, recurrent or metastatic solid malignancy that has progressed and standard therapy has been ineffective or intolerable. Phase b subjects must also have experienced disease progression after treatment with an anti PD- or PDL- agent.
Histologically proven, locally advanced unresectable or metastatic solid tumors for whom no approved therapy with demonstrated clinical benefit is available or standard treatment was declined.
Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor or lymphoma by pathology report and who has received, or been intolerant to, all treatment known to confer clinical benefit. Solid tumors and lymphomas of any type are eligible for enrollment.
Histologically or cytologically-documented, advanced solid tumor of one of the following types:
Advanced melanoma or PD-L-positive advanced, relapsed, or refractory solid tumor or lymphoma
Has a diagnosis of locally advanced or metastatic solid tumor
Have advanced or metastatic cancer (solid tumors) and be an appropriate candidate for experimental therapy.
Advanced solid tumors
Patients with advanced and/or metastatic, histologically documented solid tumors.
Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
Histologically-proven, unresectable locally advanced or metastatic solid tumors of any histology that test positive for B-H expression on tumor cells or vasculature for whom no approved therapy with demonstrated clinical benefit is available. For all tumor types, the requirement for previous systemic therapy may be waived if a patient was intolerant of or refused standard first-line therapy
If the study Sponsor decides to evaluate additional solid tumors, subjects must satisfy following criteria to be included in the study: Has a pathologically documented advanced solid tumor.
Subjects must have histologically confirmed solid tumor malignancy that is metastatic or treatment refractory cancers which are not curable or do not have known palliative measures or treatments that are associated with a survival advantage (as defined by the subject or the physician investigator); enrollment of subjects with tumors that can be safely biopsied is encouraged
Histologically confirmed, unresectable advanced solid malignancy with documented disease progression after at least  prior systemic therapy
Patient must have recurrent or advanced cancer (i.e., solid tumors) for whom standard therapy offers no curative potential.
Regimen A only (monotherapy): Subjects with advanced metastatic solid tumors
Regimen B only (combination with trastuzumab): Subjects with advanced metastatic HER+ solid tumors
Regimen C only (combination with cetuximab): Subjects with advanced metastatic EGFR+ solid tumors
Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.
Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
Locally advanced or metastatic solid tumors that have exhausted standard of care therapy
Advanced solid tumors
Previously treated, pathologically confirmed, locally advanced or metastatic solid tumors with measurable disease;
During dose escalation, subjects with advanced solid tumors that have progressed following at least one standard regimen
Subjects must have a histologically or cytologically proven advanced solid tumor malignancy for which palliative radiation is recommended. In solid tumors where pembrolizumab has been approved for use, patients may receive pembrolizumab as indicated, in the context of this protocol; in solid tumors where pembrolizumab has not been approved for use, the following criteria apply:\r\n* Patients must be resistant to at least  prior conventional chemotherapy regimen or other standard of care regimen,\r\n* Patient must have no remaining conventional treatment options proven to provide long-term disease control, and\r\n* Patient has declined other conventional treatment options\r\nPalliative radiation therapy may be recommended for primary tumor and/or any metastatic site that is accessible to biopsy
Stage IV or locally advanced histologically confirmed solid tumors for which no alternative therapies with proven survival advantage are available
Histologically or cytologically documented locally advanced, inoperable or metastatic solid tumors with documented AKT, ,  genetic alterations, activating PIK mutations, PTEN-null, or other known actionable PTEN mutations
Patients with a histologically-confirmed, advanced solid malignancy for which pembrolizumab is approved (Parts C and D)
For dose escalation cohort: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who have failed at least one line of therapy
Arm : histologically or cytologically confirmed solid tumors that are advanced that gemcitabine-based treatment is considered a clinically appropriate option
Arm : histologically or cytologically confirmed solid tumors that are advanced that gemcitabine plus cisplatin treatment is considered a clinically appropriate option
(Combination Therapy - Part E and Part F) -- Histologically or cytologically confirmed advanced or metastatic solid malignancy for which pembrolizumab treatment is approved. In Part F, other advanced solid tumor indications may be eligible as identified by the Sponsor.
For the dose escalation phase, patients must have histologically confirmed metastatic solid tumor (metastatic or unresectable, locally advanced gastrointestinal [GI] cancers [e.g., esophageal, colorectal, pancreatic and others]), ovarian and breast cancers; the malignancy should be considered incurable using standard treatment; for the extension cohort (N=) and for the expansion phase (N=), patients with advanced breast cancer (N=), advanced gastrointestinal cancer (N=) and advanced ovarian (N=) will be enrolled; all patients enrolled on the extension and expansion phase will be required to have measurable disease
Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
advanced or metastatic solid tumor (Part A)
Subject must have an advanced solid tumor
Part : Has a histologically- or cytologically-documented, locally-advanced or metastatic solid malignancy and has received ? and < prior line of cancer treatment regimen(s).
cMET dysregulated advanced solid tumor
Histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressive disease at study entry, and have received at least one line of prior systemic therapy or for which no alternative therapy to prolong survival exists
Histologically confirmed advanced solid tumors with measurable lesions per RECIST v. that are considered nonamenable to surgery or other curative treatments or procedures.
Diagnosis during dose escalation (Part ) - Pathologically documented, definitively diagnosed non-resectable advanced solid tumor.
Group  - patients must have a pathologically documented, definitively diagnosed advanced solid tumor with a RET alteration, other than NSCLC and MTC.
For the expansion part: Patients with relapsed, advanced and/or metastatic solid tumors who are not candidates for standard therapy
Part : advanced solid tumor or hematologic malignancy
Part : select advanced solid tumor or hematologic malignancy
During dose escalation, subjects with advanced solid tumors (except for primary CNS metastases) that have progressed following at least one standard regimen
For dose escalation, locally advanced and/or metastatic gastrointestinal (GI) solid tumor in participants who have progressed on a standard therapy, are intolerant to SOC, and/or are non-amenable to SOC and other solid tumors expressing CEA. Only locally advanced and/or metastatic colorectal cancer participants should be included in the scheduled comparison expansion
Phase : Subjects with advanced or metastatic solid tumors.
Subject must have locally advanced or metastatic solid tumor;
Subjects with any previously treated advanced (metastatic or refractory) solid tumor
Subjects must have a previously treated advanced solid tumor to be eligible
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a NTRK, NTRK, NTRK, ROS, or ALK molecular alteration.
Men and women,  years or older, with histologically or cytologically-confirmed, advanced solid tumors, Non-Hodgkin Lymphona (NHL), Multiple Myloma (MM), or advanced unresectable solid tumors limited to the tumor types below.
Part B only: . Histologically or cytologically confirmed, molecularly selected (i.e. BRAFV positive and/or PIK mutation positive) advanced solid tumors. Prior molecular characterization should be based using a regulatory approved assay or analytically validated assay.
Subjects must have histologically confirmed, locally advanced or metastatic solid cancers of the following histological types:
Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
Has histologically or cytologically confirmed advanced, measurable or non-measurable metastatic solid tumors for which the patients have no available therapy to convey clinical benefit Expansion Phase only: The target population should include at least
Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor.
Subjects can be treatment naive for metastatic or incurable locally advanced HPV- positive solid tumors or can have one prior line of treatment
Have recurrent or metastatic solid tumors
Cohort C: patients with histologically proven metastatic or locally advanced non-colorectal MSI solid tumor malignancies
Cohort D: Patients with histologically proven metastatic or locally advanced solid tumor malignancies that are microsatellite stable with a documented mutation burden level measured at >  mutations per megabase pairs (MB)
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent in adult patients with: NSCLC, TNBC, HR+ breast cancer, recurrent platinum sensitive ovarian cancer, UC, CRPC, and other advanced solid tumors with a BRCA or ATM gene defect
Histologically or cytologically documented advanced or metastatic solid tumors for which established therapy either does not exist or has proven ineffective or intolerable
Presumptive or histologically confirmed advanced or metastatic non-curable solid tumor (if limited to a single lesion, and may not be a candidate for curative surgery or radiation therapy).
Histologically confirmed advanced or metastatic non-curable solid tumor (if limited to a single lesion may not be a candidate for curative surgery or radiation therapy). Successful vaccine manufacture has resulted from tissue/fluid obtained from the following major organ systems: digestive, endocrine, reproductive, respiratory, and urinary.Individuals manufactured under CL-PTL  (Phase II Ovarian) may be eligible for enrollment without advanced or metastatic disease.
Locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed standard of care therapy
Concurrent metastatic solid tumors
Pathologic diagnosis of solid tumor malignancy that is locally advanced or metastatic at time of Screening with documented HER expression.
Pathologically documented diagnosis of advanced solid tumor malignancy that progressed after appropriate prior therapy or has no potential for cure with currently available treatments.
Diagnosis of one of the following advanced solid tumors for which standard therapy either does not exist or has proven ineffective, intolerable or inacceptable for the participant: NMC;TNBC; NSCLC; or CRPC
Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor
Metastatic and/or locally advanced malignant solid tumors enriched in tumor types known to be mesothelin expressing
Histologically confirmed metastatic and/or advanced malignant mesothelin-positive solid tumors as determined by central pathology lab review
Advanced or metastatic solid tumor that has progressed or was not responsive to standard therapy
Diagnosis of an advanced solid tumor malignancy.
Locally advanced or metastatic solid tumors;
Treatment Group A (TGA): Part  and Part : Any advanced solid tumor or lymphoma; Part : Histologically confirmed disease in specific solid tumors and lymphomas
Relapsed or progressive advanced solid tumor malignancies
Histologically or cytologically documented, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable
Advanced solid tumors with histologic diagnosis confirming cancer
Histologically or cytologically documented advanced or metastatic solid tumors for which established therapy either does not exist or has proven ineffective or intolerable
Part  (enrollment closed): an advanced, incurable solid tumor
Part  (enrollment closed): an advanced, incurable solid tumor for whom a taxane would be considered a reasonable chemotherapy option
Advanced solid tumor malignancy
Locally advanced or metastatic solid KRAS-mutant tumors, for which standard therapies do not exist, have proven ineffective or intolerable or are considered inappropriate
Dose escalation phase: Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors and malignant lymphomas) who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST . or Cheson  criteria).
For expansion cohort only: Subjects with histologically or cytologically proven metastatic breast cancer (with and without AKT EK (GA) mutation) or subjects with known AKT EK (GA) mutation in any other advanced solid tumor with at least one line of chemotherapy in the metastatic setting and not amenable to surgery with curative intent
Patients with a documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic.
Histologically or cytologically confirmed: solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative treatment is no longer effective (Part ); any type of advanced or refractory solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which standard curative treatment is no longer effective (Part ); advanced or refractory squamous non-small cell lung cancer (Cohort A, Part ), advanced or refractory small cell lung cancer (Cohort B, Part ), advanced or refractory breast cancer (Cohort C, Part ), any type of advanced or refractory solid malignancy (excluding lymphoma) ([consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme (GBM), ovarian or prostate]) (Cohort D, Part ), advanced or refractory non small cell lung cancer(Cohort E, Part ), any type of advanced or refractory solid malignancy (consisting of one of the following: Breast, Urothelial, GBM, Ovarian, Head & Neck, Esophageal, Gastric, and Cholangiocarcinoma) (Cohort F, Part )
Subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is considered appropriate
Phase : Subjects with advanced or metastatic solid tumors.
Dose Escalation Phase: Patients with advanced or metastatic solid tumors for which no standard therapy is available. For Schedule  only: patients with colorectal cancer with liver metastasis. Dose Expansion Phase: Previously treated, metastatic or advanced recurrent malignancy with  of the following diagnoses, which has been confirmed histologically or cytologically:
Histologically or cytologically documented, locally advanced or metastatic solid tumors or lymphoma for which standard therapy either does not exist or has proven ineffective or intolerable
locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy.
Subjects with advanced or metastatic solid tumors (non-hematologic refractory to or relapsed from standard therapies or for which there is no known effective treatment during dose escalation
Subjects must have a pathologically documented, definitively diagnosed, advanced solid tumor
Adults with a primary diagnosis of any advanced solid tumor cancer within the last  years
Histologically documented advanced or metastatic solid tumors or lymphomas
Patient is at least  weeks post-diagnosis of an incurable (locally advanced or metastatic) solid malignancy
Patient with a diagnosis of advanced cancer (metastatic or recurrent incurable solid tumors excluding prostate cancer)
Metastatic solid tumors
A new diagnosis (within  months) of advanced cancer and/or patients receiving ongoing care from a medical oncologist (solid tumors) or a new recurrence of the primary cancer in an advanced stage
Incurable solid tumor malignancy
Diagnosis of a metastatic or incurable solid tumor
Subjects must be at the recurrent/metastatic setting, with selected advanced solid tumors.
Histologically documented advanced or metastatic solid tumors.
For Part : Histologically- or cytologically-confirmed diagnosis of unresectable GIST or another advanced solid tumor. Patients with unresectable GIST must have disease that has progressed following imatinib and at least  of the following: sunitinib, regorafenib, sorafenib, dasatinib, pazopanib or an experimental kinase-inhibitor agent, or disease with a D mutation in the PDGFR? gene. Patients with an advanced solid tumor other than GIST must have relapsed or refractory disease without an available effective therapy. OR For Part :
Diagnosis of a proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor
Patients with histopathologic diagnosis of a solid tumor. All solid tumors will be considered, but patients with breast, pancreas, and colorectal masses will be prioritized.
Dose Escalation Segment: histologically and / or cytological confirmed locally advanced, recurrent or relapsed, or metastatic incurable solid malignancy with no limit on the number of prior lines of standard therapy.
Subject has been diagnosed with an advanced solid malignancy; advanced solid malignancy is defined as loco regional or systemic metastatic disease of at least  cm in diameter; tumor types allowed include: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head & neck cancer; subjects with primary or metastatic skin disease only are excluded from participation in this study
Have a confirmed diagnosis of advanced, refractory solid tumors and tumor progression or treatment intolerance to at least  prior therapy.
Confirmed advanced solid tumor or hematologic malignancy
Histologically or cytologically documented, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable
Part : Subjects with advanced or metastatic solid tumors.
Part : Subjects with advanced or metastatic solid tumors
Advanced Solid Malignancies: Histologically documented metastatic or locally advanced, incurable solid malignancy (Parts A and B); histologically documented metastatic or locally advanced, incurable solid malignancy for which gemcitabine is clinically appropriate (e.g., non-small cell lung, breast, ovarian, pancreatic, and renal cancer); histologically documented metastatic or locally advanced, incurable solid malignancy for which pembrolizumab (Part D) or nivolumab (Part E) is approved. NOTE: Parts D and E only: Subject has either () received treatment with pembrolizumab or nivolumab for ? months with a best response of stable disease and plans to continue treatment with either pembrolizumab or nivolumab in accordance with package insert; or () is not currently taking, but is eligible for treatment with, pembrolizumab or nivolumab in accordance with the approved indications for each as referenced in the package insert.
